Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

Basel, November 14, 2016 - Novartis today announced that the US Food and Drug Administration (FDA) granted Priority Review to the PKC412 (midostaurin) new drug application (NDA) for the treatment of acute myeloid leukemia (AML) in newly-diagnosed...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials